Health
J&J COVID-19 vaccine is 72% effective in the U.S., and 66% overall in large trial – Reuters
Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will…
(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.
FILE PHOTO: A vial and sryinge are seen in front of a displayed Johnson&Johnson logo in this illustration taken January 11, 2021. REUTERS/Dado Ruvic
In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from…
-
General19 hours agoCoalition seeks to rebuild ties with Indian community
-
Noosa News22 hours agoOver $50K raised for Noosa’s Oz Bayldon after brain aneurysm
-
Business19 hours agoHow to retire in your 50s with ASX shares
-
Noosa News21 hours agoNational Drought Forum convenes in SA to put policy under scrutiny